NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $28.35 +0.98 (+3.58%) Closing price 04:00 PM EasternExtended Trading$28.25 -0.10 (-0.35%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Adaptive Biotechnologies Stock (NASDAQ:ADPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADPT alerts:Sign Up Key Stats Today's Range$27.31▼$28.4150-Day Range$22.27▼$29.5752-Week Range$12.00▼$29.96Volume1.58 million shsAverage Volume2.32 million shsMarket Capitalization$4.52 billionP/E RatioN/ADividend YieldN/APrice Target$28.94Consensus RatingModerate Buy Company Overview Adaptive Biotechnologies is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and therapeutic applications. Its technologies analyze immune-cell receptors, including T-cell and B-cell receptors, to help identify and measure immune responses associated with cancer, infectious diseases and other conditions. The company’s product portfolio includes immunoSEQ, a research and clinical platform for immune-repertoire sequencing, and clonoSEQ, a diagnostic test used to detect and monitor measurable residual disease in certain blood cancers. clonoSEQ is used in conditions including multiple myeloma, chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia. Adaptive also uses immune-receptor data in collaboration with biopharmaceutical companies developing targeted medicines and immunotherapies. Founded in 2009 by brothers Chad Robins and Harlan Robins, Adaptive Biotechnologies is headquartered in Seattle, Washington. Its services and platforms support pharmaceutical companies, academic researchers, healthcare providers and patients in the United States and other markets. Chad Robins serves as the company’s chief executive officer, while Harlan Robins is a co-founder and scientific leader.AI Generated. May Contain Errors. Read More Adaptive Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreADPT MarketRank™: Adaptive Biotechnologies scored higher than 32% of companies evaluated by MarketBeat, and ranked 718th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Adaptive Biotechnologies is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAdaptive Biotechnologies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adaptive Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.40) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -69.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -69.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 19.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.96% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 7.89.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 15.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentAdaptive Biotechnologies has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Adaptive Biotechnologies this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,434,352.00 in company stock.Percentage Held by Insiders5.70% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADPT Stock News HeadlinesAdaptive Biotechnologies consensus price target increased by 11.11% to $28.05October 2 at 8:12 AM | msn.comAdaptive Biotechnologies slips as recent rally cools despite no clear new negative catalystOctober 1 at 1:51 PM | quiverquant.comQMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.October 2 at 1:00 AM | Paradigm Press (Ad)The Goldman Sachs Group Begins Coverage on Adaptive Biotechnologies (NASDAQ:ADPT)October 1 at 1:48 AM | americanbankingnews.comAdaptive Biotechnologies Spotlights MRD Testing In Myeloma Cure CriteriaSeptember 26, 2026 | rttnews.comAdaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline UpdateSeptember 25, 2026 | finance.yahoo.comInsider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $3,238,292.36 in StockSeptember 19, 2026 | insidertrades.comSusan Bobulsky Sells 1,195 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) StockSeptember 18, 2026 | insidertrades.comSee More Headlines ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $16.24 on January 1st, 2026. Since then, ADPT shares have increased by 74.6% and is now trading at $28.35. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Corporation (NASDAQ:ADPT) posted its quarterly earnings results on Wednesday, July, 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.12. Adaptive Biotechnologies's revenue was up 21.5% compared to the same quarter last year. Read the conference call transcript. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $278 million in an initial public offering on Thursday, June 27th 2019. The company issued 15,000,000 shares at $18.00-$19.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings7/29/2026Today10/02/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ADPT's financial health is in the Green zone, according to TradeSmith. ADPT has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ADPT CIK1478320 Webwww.adaptivebiotech.com Phone(206) 659-0067Fax206-659-0667Employees624Year Founded2009Price Target and Rating Average Price Target for Adaptive Biotechnologies$28.94 High Price Target$35.00 Low Price Target$19.00 Potential Upside/Downside+2.1%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.50 million Net Margins-20.73% Pretax Margin-20.77% Return on Equity-36.81% Return on Assets-13.77% Debt Debt-to-Equity Ratio2.22 Current Ratio4.79 Quick Ratio4.68 Sales & Book Value Annual Sales$276.98 million Price / Sales16.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book19.29Miscellaneous Outstanding Shares159,600,000Free Float150,499,000Market Cap$4.52 billion OptionableOptionable Beta2.09 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ADPT) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
